Search hospitals > California > Oakland
UCSF Benioff Children's Hospital Oakland
Claim this profileOakland, California 94609
Global Leader in Sickle Cell Anemia
Global Leader in Leukemia
Conducts research for Tumors
Conducts research for Sickle Cell Disease
Conducts research for Lymphoma
250 reported clinical trials
17 medical researchers
Summary
UCSF Benioff Children's Hospital Oakland is a medical facility located in Oakland, California. This center is recognized for care of Sickle Cell Anemia, Leukemia, Tumors, Sickle Cell Disease, Lymphoma and other specialties. UCSF Benioff Children's Hospital Oakland is involved with conducting 250 clinical trials across 384 conditions. There are 17 research doctors associated with this hospital, such as Carla B. Golden, Jennifer G. Michlitsch, Paul Harmatz, and Anurag Agrawal, MD.Area of expertise
1Sickle Cell Anemia
Global LeaderHbSS positive
HbSβ0 positive
HLA-A positive
2Leukemia
Global LeaderStage II
CD19 positive
Stage I
Top PIs
Carla B. GoldenUCSF Benioff Children's Hospital Oakland7 years of reported clinical research
Expert in Tumors
Expert in Cancer
43 reported clinical trials
83 drugs studied
Jennifer G. MichlitschUCSF Benioff Children's Hospital Oakland7 years of reported clinical research
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
22 reported clinical trials
76 drugs studied
Paul HarmatzUniversity of California San Francisco, Benioff Children's Hospital1 year of reported clinical research
Expert in Mucopolysaccharidosis
Studies Hunter Syndrome
14 reported clinical trials
17 drugs studied
Anurag Agrawal, MDUCSF Benioff Children's Hospital Oakland-3 years of reported clinical research
Studies Neuroblastoma
Studies Medulloblastoma
5 reported clinical trials
9 drugs studied
Clinical Trials running at UCSF Benioff Children's Hospital Oakland
Acute Lymphoblastic Leukemia
Non-Hodgkin's Lymphoma
Neuroblastoma
Langerhans Cell Histiocytosis
Osteosarcoma
Germ Cell Tumors
Acute Myeloid Leukemia
Rhabdomyosarcoma
Brain Tumor
Acute Leukemia
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy vs. standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Stem Cell Transplantation
for Leukemia
This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical \[haplo\]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). HCT is considered standard of care treatment for patients with high-risk acute leukemia and MDS. In HCT, patients are given very high doses of chemotherapy and/or radiation therapy, which is intended to kill cancer cells that may be resistant to more standard doses of chemotherapy; unfortunately, this also destroys the normal cells in the bone marrow, including stem cells. After the treatment, patients must have a healthy supply of stem cells reintroduced or transplanted. The transplanted cells then reestablish the blood cell production process in the bone marrow. The healthy stem cells may come from the blood or bone marrow of a related or unrelated donor. If patients do not have a matched related donor, doctors do not know what the next best donor choice is. This trial may help researchers understand whether a haplo related donor or a MUD HCT for children with acute leukemia or MDS is better or if there is no difference at all.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at UCSF Benioff Children's Hospital Oakland?
UCSF Benioff Children's Hospital Oakland is a medical facility located in Oakland, California. This center is recognized for care of Sickle Cell Anemia, Leukemia, Tumors, Sickle Cell Disease, Lymphoma and other specialties. UCSF Benioff Children's Hospital Oakland is involved with conducting 250 clinical trials across 384 conditions. There are 17 research doctors associated with this hospital, such as Carla B. Golden, Jennifer G. Michlitsch, Paul Harmatz, and Anurag Agrawal, MD.